COMMUNIQUÉS West-GlobeNewswire

Cosmos Health Enters New Nanotechnology R&D Program to Develop Next-Generation Nutraceutical Formulas with Enhanced Phytochemical Efficacy
31/10/2025
CHICAGO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced the initiation of a new [...]
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
31/10/2025
COPENHAGEN, Denmark, October 31, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 4.99% [...]
Immuron Announces Clinical Trial Update
31/10/2025
IMM-529 IND: currently under review, FDA request for Information – minor updates to clinical protocol completed and submitted Travelan ® P2TD (n=851) Uniformed Services University study topline data delayed to the end [...]
Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award
31/10/2025
Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic conditions First and only therapy to specifically target the IL-4 and IL-13 [...]
BioStem Technologies Reports Positive Top-Line Clinical Results Demonstrating Superior Outcomes with BioRetain® Allograft in Diabetic Foot Ulcers
31/10/2025
Randomized controlled trial results published in the International Journal of Tissue Repair demonstrate BioRetain® allografts significantly improve probability of achieving lasting wound closure versus standard of care [...]
Upstream Bio to Participate in Upcoming November Investor Conferences
31/10/2025
WALTHAM, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today [...]
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
31/10/2025
Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous alignment with FDA Patients randomized to either 10 or 20 mg/kg of muzastotug, in combination with [...]
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025
31/10/2025
PRINCETON, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November. 2025 [...]
Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report
31/10/2025
Highlights New analysis of ATH434-201 double blind trial strengthens efficacy signal at high dose level Positive data from ATH434-202 open-label trial demonstrates similar treatment effect in advanced MSA as observed in [...]
Vireo Growth Inc. to Release Third Quarter 2025 Results on November 12, 2025
31/10/2025
MINNEAPOLIS, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), today announced that it will release its financial results for its third fiscal quarter ended [...]
Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025
31/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced upcoming presentations, including three Late Breaking Science presentations related to MAPLE-HCM [...]
TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update
31/10/2025
Conference Call to be Held Monday, November 3, 2025, at 8:30 am ET NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, November [...]
Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
31/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct [...]
Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy
31/10/2025
Vancouver, Canada, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel [...]
Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025
31/10/2025
COPENHAGEN, Denmark, October 31, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its [...]
HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead
31/10/2025
NEW YORK and VIENNA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, “HOOKIPA”) today announced the completion of the sale of its assets related to HOOKIPA’s HB-400 program and certain of its assets [...]
Alps Announces Closing of Business Combination with Globalink Investment Inc.
31/10/2025
Alps ordinary shares to list on the Nasdaq under the symbol “ALPS” on October 31, 2025 KUALA LUMPUR, Malaysia and NEWARK, Del., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Alps Group Inc (the “ Company ” or “ Alps Group ”), the [...]
Certara to Participate in Upcoming Investor Conferences
31/10/2025
RADNOR, Pa., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor [...]
Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2025
31/10/2025
Tokyo, Japan and Cambridge, UK, 31 October 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third quarter and nine [...]

Pages